ACE and peripheral arterial disease: The antiatherogenic effect of the ACE inhibitor ramipril was confirmed in the Heart Outcomes Prevention Evaluation (HOPE) study, where ramipril provided equal relative protection against myocardial infarction, stroke and cardiovascular death in patients with PAD as in other high-risk groups [43].